Ligand id: 7988

Name: nimotuzumab

No information available.
Summary of Clinical Use
Nimotuzumab has been approved in some countries (including China, India and the Philippines) for the treatment of squamous cell carcinomas of the head and neck. In 2004 the EMA granted orphan designation for nimotuzumab as a treatment for high grade glioma and pancreatic cancer, however in 2007 the drug's manufacturer requested withdrawl of its application for EU-wide marketing authorisation. has many registered Phase III nimotuzumab trials, for indications including esophageal squamous cell carcinoma, gastric cancer, nasopharyngeal carcinoma, recurrent or persistent cervical cancer and glioblastoma multiforme. Click here to link to this list.
Mechanism Of Action and Pharmacodynamic Effects
EGFR is expressed on the surface of some tumour cells. When activated, EGFR helps the tumour cells grow, multiply and spread. By blocking EGFR, nimotuzumab is expected to slow down cancer progression.